Does affinity of ACE inhibitors to the tissue rennin-angiotensin-aldosterone system, have any practical significance?
Individual ACEIs differ from each other in their structure and pharmacokinetic parameters. Tissue RAAS affinity is one of many properties determining the effect of drug. To individualize therapy in everyday practice, such features of ACEI as duration of action, time of antihypertensive effect development, and elimination route are more important. Selection of a drug should be based on its major pharmacokinetic parameters, individual patient characteristics, and results of large, randomized clinical studies, which allow a physician predicting to what extent the use of some or another drug would help a specific patient to achieve goals of the treatment